Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.

Published in: The Annals of pharmacotherapy (2024)

The characteristics of pirtobrutinib render it useful in the treatment of B-cell malignancies no longer responding to a previous BTK inhibitor, and results from ongoing clinical trials may support future expanded use.

Keyphrases

clinical trial
randomized controlled trial
current status
phase ii
phase iii
smoking cessation